MedTrace Logo

A Study of LY3200882 in Participants With Solid Tumors

NCT02937272 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2026-04-03

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Conditions

Interventions

DRUG

LY3200882

Administered orally

DRUG

LY3300054

Administered intravenously

DRUG

Gemcitabine

Administered intravenously

DRUG

nab-Paclitaxel

Administered intravenously

DRUG

Cisplatin

Administered intravenously

RADIATION

Intensity Modulated Radiotherapy

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-21
Primary Completion
2020-02-27
Completion
2027-08-31

Countries

  • United States
  • Australia
  • Canada
  • France
  • Germany
  • Italy
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02937272 on ClinicalTrials.gov